Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
DNTH Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DNTH Stock 12 Month Forecast
Average Price Target
$42.60
▲(113.11% Upside)
| Highest Price Target$52.00 | Average Price Target$42.60 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
Reiterated
03/12/25
TD Cowen
Assigned
03/12/25
H.C. Wainwright
Reiterated
03/12/25
Stifel Nicolaus
Reiterated
03/12/25
Wedbush
Reiterated
03/12/25
Citi
Reiterated
03/11/25
Robert W. Baird
$58
Buy
190.15%
Upside
Reiterated
11/11/24
Dianthus Therapeutics' Strategic Advancements and Accelerated Drug Development Drive 'Buy' Rating
Oppenheimer
$52
Buy
160.13%
Upside
Assigned
11/11/24
Dianthus price target raised to $52 from $48 at OppenheimerDianthus price target raised to $52 from $48 at Oppenheimer
Guggenheim
―
Buy
―
Reiterated
10/04/24
Guggenheim reiterates Buy Rating on Dianthus Therapeutics (DNTH)Guggenheim analyst Yatin Suneja reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).
Cantor Fitzgerald
―
Buy
―
Initiated
06/27/24
Dianthus initiated with an Overweight at Cantor FitzgeraldDianthus initiated with an Overweight at Cantor Fitzgerald
Raymond James
$34→$51
Buy
155.13%
Upside
Reiterated
04/18/24
Dianthus price target raised to $51 from $34 at Raymond JamesDianthus price target raised to $51 from $34 at Raymond James
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
Reiterated
03/12/25
TD Cowen
Assigned
03/12/25
H.C. Wainwright
Reiterated
03/12/25
Stifel Nicolaus
Reiterated
03/12/25
Wedbush
Reiterated
03/12/25
Citi
Reiterated
03/11/25
Robert W. Baird
$58
Buy
190.15%
Upside
Reiterated
11/11/24
Dianthus Therapeutics' Strategic Advancements and Accelerated Drug Development Drive 'Buy' Rating
Oppenheimer
$52
Buy
160.13%
Upside
Assigned
11/11/24
Dianthus price target raised to $52 from $48 at OppenheimerDianthus price target raised to $52 from $48 at Oppenheimer
Guggenheim
―
Buy
―
Reiterated
10/04/24
Guggenheim reiterates Buy Rating on Dianthus Therapeutics (DNTH)Guggenheim analyst Yatin Suneja reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).
Cantor Fitzgerald
―
Buy
―
Initiated
06/27/24
Dianthus initiated with an Overweight at Cantor FitzgeraldDianthus initiated with an Overweight at Cantor Fitzgerald
Raymond James
$34→$51
Buy
155.13%
Upside
Reiterated
04/18/24
Dianthus price target raised to $51 from $34 at Raymond JamesDianthus price target raised to $51 from $34 at Raymond James
DNTH Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Feb 25
Mar 25
Strong Buy
5
5
7
6
8
Buy
3
3
3
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
8
10
9
11
Each month's total comprises the sum of three months' worth of ratings.
DNTH Financial Forecast
DNTH Stock Forecast FAQ
What is DNTH’s average 12-month price target, according to analysts?
Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is $42.60.
What is DNTH’s upside potential, based on the analysts’ average price target?
Dianthus Therapeutics has 113.11% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DNTH a Buy, Sell or Hold?
Dianthus Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Dianthus Therapeutics’s price target?
The average price target for Dianthus Therapeutics is $42.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $36.00. The average price target represents 113.11% Increase from the current price of $19.99.
The highest analyst price target is $52.00 ,the lowest forecast is $36.00. The average price target represents 113.11% Increase from the current price of $19.99.
What do analysts say about Dianthus Therapeutics?
Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of DNTH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.